LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 25

Search options

  1. Article ; Online: Superiorly Based Posterior Pharyngeal Flaps: Using A Care Pathway to Optimize Speech and Airway Outcomes.

    Butterfield, James / Pencek, Megan / Sweitzer, Keith / Marrinan, Eileen / Connolly, Heidi / Neimanis, Sara / Morrison, Clinton

    Annals of plastic surgery

    2024  Volume 92, Issue 4S Suppl 2, Page(s) S101–S104

    Abstract: Background: Pharyngeal flap (PF) surgery is effective at improving velopharyngeal sufficiency, but historical literature shows a concerning prevalence rate of obstructive sleep apnea (OSA), reported as high as 20%. Our institution has developed a ... ...

    Abstract Background: Pharyngeal flap (PF) surgery is effective at improving velopharyngeal sufficiency, but historical literature shows a concerning prevalence rate of obstructive sleep apnea (OSA), reported as high as 20%. Our institution has developed a protocol to minimize risk of postoperative obstructive complications and increase safety of PF surgery. We hypothesize that (1) preoperative staged removal of significant adenotonsillar tissue along with (2) multiview videofluoroscopy to guide patient-specific surgical approach via appropriately sized PFs can result in excellent speech outcomes while limiting occurrence of OSA.
    Methods: This was a retrospective chart review of all patients with velopharyngeal insufficiency (VPI) (aged 2-20 years) seen at the University of Rochester from 2015 to 2022 undergoing PF surgery to correct VPI. Nasopharyngoscopy was used for surgical planning and airway evaluation. Patients with tonsillar and adenoid hypertrophy underwent staged adenotonsillectomy at least 2 months before PF. Multiview videofluoroscopy was used to identify anatomic causes of VPI and to determine PF width. Patients underwent polysomnography and speech evaluation before and at least 6 months after PF surgery.
    Results: Forty-one children aged 8.5 ± 4.1 years (range, 4 to 18 years) who underwent posterior PF surgery for VPI were identified. This included 10 patients with 22q11.2 deletion and 4 patients with Pierre Robin sequence. Thirty-nine patients had both pre- and postoperative speech data and underwent both a pre- and postoperative sleep study. Polysomnography showed no significant difference in obstructive apnea-hypopnea index after posterior PF surgery (obstructive apnea-hypopnea index preop, 1.3 ± 1.2 events per hour; postop, 1.7 ± 2.1 events per hour; P = 0.111). Significant improvements in speech outcome were seen in patients who underwent PF (modified Pittsburgh score preop, 11.52 ± 1.37; postop, 1.09 ± 2.35; P < 0.05).
    Conclusions: Use of preoperative staged adenotonsillectomy as well as patient-specific PF dimensions results in effective resolution of VPI and a low risk of OSA.
    MeSH term(s) Child ; Humans ; Speech ; Retrospective Studies ; Critical Pathways ; Pharynx/surgery ; Velopharyngeal Insufficiency/surgery ; Velopharyngeal Insufficiency/complications ; Sleep Apnea, Obstructive/etiology ; Postoperative Complications/epidemiology ; Treatment Outcome
    Language English
    Publishing date 2024-03-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 423835-7
    ISSN 1536-3708 ; 0148-7043
    ISSN (online) 1536-3708
    ISSN 0148-7043
    DOI 10.1097/SAP.0000000000003859
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Inflammation and Cytopenias in a Well-Appearing Infant With SARS-CoV-2.

    Karim, Sabrina A / Weiss, Cary N / Marrinan, Jaclyn E / Herlihy, Julie M

    Clinical pediatrics

    2021  Volume 61, Issue 2, Page(s) 116–119

    MeSH term(s) COVID-19/complications ; COVID-19/physiopathology ; Humans ; Infant ; Inflammation/etiology ; Inflammation/physiopathology ; Male ; Neutropenia/etiology ; Neutropenia/physiopathology
    Language English
    Publishing date 2021-09-28
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 207678-0
    ISSN 1938-2707 ; 0009-9228
    ISSN (online) 1938-2707
    ISSN 0009-9228
    DOI 10.1177/00099228211048599
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Simultaneous Furlow Palatoplasty and Tonsillectomy for the Treatment of Velopharyngeal Insufficiency and Tonsillar Hypertrophy.

    Pencek, Megan / Butterfield, James / Escandón, Joseph M / Sweitzer, Keith / Smith, Hannah / Catanzaro, Michael / Marrinan, Eileen / Morrison, Clinton

    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association

    2023  , Page(s) 10556656231176864

    Abstract: Objective: To determine whether performing tonsillectomy at the time of Furlow palatoplasty for the treatment of cleft palate related velopharyngeal insufficiency (VPI) incurs increased surgical complications or compromises speech outcomes.: Design: ... ...

    Abstract Objective: To determine whether performing tonsillectomy at the time of Furlow palatoplasty for the treatment of cleft palate related velopharyngeal insufficiency (VPI) incurs increased surgical complications or compromises speech outcomes.
    Design: A retrospective review of patients who had Furlow palatoplasty and the outcomes of surgery in the treatment of cleft palate related VPI.
    Setting: A single academic center between January 2015 and January 2022.
    Participants: Patients with submucous cleft (SMC) palate or patients with prior straight line primary palatoplasty presenting with VPI.
    Interventions: Simultaneous conversion Furlow palatoplasty and tonsillectomy.
    Main outcome measure(s): Primary outcome measures include preoperative and postoperative Modified Pittsburgh Weighted Speech Scale (mPWSS), and postoperative surgical complications.
    Results: Eight patients (25%) underwent Furlow palatoplasty and concomitant tonsillectomy, while 24 patients (75%) underwent Furlow palatoplasty alone. A significantly lower median postoperative mPWSS score, corresponding to better velopharyngeal function, was reported for patients in the Furlow-tonsillectomy group (0, IQR 0-0) compared to the Furlow only group (1, IQR 0-9, p  =  0.046). No surgical complications were encountered in either group. Five patients (20.8%) in the Furlow only group required subsequent surgery for persistent VPI. No patients in the Furlow-tonsillectomy group required additional surgical treatment for VPI (0%, p  =  0.16).
    Conclusions: Tonsillectomy at time of Furlow palatoplasty is utilized in patients with both VPI and baseline tonsillar hypertrophy to lessen the risk of postoperative obstructive breathing. Tonsillectomy performed concurrently with Furlow palatoplasty is safe, without increased risk of surgical complications, and does not compromise post-Furlow palatoplasty speech outcomes.
    Language English
    Publishing date 2023-05-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1069409-2
    ISSN 1545-1569 ; 0009-8701 ; 1055-6656
    ISSN (online) 1545-1569
    ISSN 0009-8701 ; 1055-6656
    DOI 10.1177/10556656231176864
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: High concentrations of persistent organic pollutants in adult killer whales (Orcinus orca) and a foetus stranded in Ireland.

    Schlingermann, Moira / Berrow, Simon / Craig, Darren / McHugh, Brendan / Marrinan, Michael / O'Brien, Joanne / O'Connor, Ian / Mudzatsi, Engelberth / White, Philip

    Marine pollution bulletin

    2019  Volume 151, Page(s) 110699

    Abstract: Bio-accumulation of persistent organic pollutants including polychlorinated biphenyls (PCBs), brominated flame retardants and organochlorine pesticides continue to be of major concern for marine apex predators such as killer whales. The concentrations of ...

    Abstract Bio-accumulation of persistent organic pollutants including polychlorinated biphenyls (PCBs), brominated flame retardants and organochlorine pesticides continue to be of major concern for marine apex predators such as killer whales. The concentrations of 16 polychlorinated biphenyls, 7 poly-brominated diphenyl ethers (PBDEs), 1 poly-brominated biphenyl (PBB) and a range of 19 organochlorine compounds (OCs) was investigated in blubber samples from a mother-foetus pair, an adult female and an adult male killer whale stranded in Ireland between 2010 and 2017. Concentrations ranged from 1.5 mg/kg to 49.3 mg/kg lipid weight and 0.04-1.2 mg/kg lipid weight for Σ16PCBs and Σ7PBDEs respectively. Concentrations of organochlorine compounds were also investigated in the male killer whale; a Σ19OC concentration of 49.4 mg/kg lipid weight was recorded. This study shows high levels of persistent organic pollutants occur in this species of whales stranded in Ireland.
    MeSH term(s) Animals ; Environmental Monitoring ; Female ; Fetus ; Halogenated Diphenyl Ethers/metabolism ; Ireland ; Male ; Polychlorinated Biphenyls/metabolism ; Water Pollutants, Chemical/metabolism ; Whale, Killer/metabolism
    Chemical Substances Halogenated Diphenyl Ethers ; Water Pollutants, Chemical ; Polychlorinated Biphenyls (DFC2HB4I0K)
    Language English
    Publishing date 2019-11-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2001296-2
    ISSN 1879-3363 ; 0025-326X
    ISSN (online) 1879-3363
    ISSN 0025-326X
    DOI 10.1016/j.marpolbul.2019.110699
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: A cohort study of frequency, duration, and risk factors.

    Thorson, A E / Deen, G F / Bernstein, K T / Liu, W J / Yamba, F / Habib, N / Sesay, F R / Gaillard, P / Massaquoi, T A / McDonald, S L R / Zhang, Y / Durski, K N / Singaravelu, S / Ervin, E / Liu, H / Coursier, A / Marrinan, J E / Ariyarajah, A / Carino, M /
    Formenty, P / Ströher, U / Lamunu, M / Wu, G / Sahr, F / Xu, W / Knust, B / Broutet, N

    PLoS medicine

    2021  Volume 18, Issue 2, Page(s) e1003273

    Abstract: Background: Sexual transmission chains of Ebola virus (EBOV) have been verified and linked to EBOV RNA persistence in semen, post-recovery. The rate of semen persistence over time, including the average duration of persistence among Ebola virus disease ( ...

    Abstract Background: Sexual transmission chains of Ebola virus (EBOV) have been verified and linked to EBOV RNA persistence in semen, post-recovery. The rate of semen persistence over time, including the average duration of persistence among Ebola virus disease (EVD) survivors, is not well known. This cohort study aimed to analyze population estimates of EBOV RNA persistence rates in semen over time, and associated risk factors in a population of survivors from Sierra Leone.
    Methods and findings: In this cohort study from May 2015 to April 2017 in Sierra Leone, recruitment was conducted in 2 phases; the first enrolled 100 male participants from the Western Area District in the capital of Freetown, and the second enrolled 120 men from the Western Area District and from Lungi, Port Loko District. Mean age of participants was 31 years. The men provided semen for testing, analyzed by quantitative reverse transcription PCR (qRT-PCR) for the presence of EBOV RNA. Follow-up occurred every 2 weeks until the endpoint, defined as 2 consecutive negative qRT-PCR results of semen specimen testing for EBOV RNA. Participants were matched with the Sierra Leone EVD case database to retrieve cycle threshold (Ct) values from the qRT-PCR analysis done in blood during acute disease. A purposive sampling strategy was used, and the included sample composition was compared to the national EVD survivor database to understand deviations from the general male survivor population. At 180 days (6 months) after Ebola treatment unit (ETU) discharge, the EBOV RNA semen positive rate was 75.4% (95% CI 66.9%-82.0%). The median persistence duration was 204 days, with 50% of men having cleared their semen of EBOV RNA after this time. At 270 days, persistence was 26.8% (95% CI 20.0%-34.2%), and at 360 days, 6.0% (95% CI 3.1%-10.2%). Longer persistence was significantly associated with severe acute disease, with probability of persistence in this population at 1 year at 10.1% (95% CI 4.6%-19.8%) compared to the probability approaching 0% for those with mild acute disease. Age showed a dose-response pattern, where the youngest men (≤25 years) were 3.17 (95% CI 1.60, 6.29) times more likely to be EBOV RNA negative in semen, and men aged 26-35 years were 1.85 (95% CI 1.04, 3.28) times more likely to be negative, than men aged >35 years. Among participants with both severe acute EVD and a higher age (>35 years), persistence remained above 20% (95% CI 6.0%-50.6%) at 1 year. Uptake of safe sex recommendations 3 months after ETU discharge was low among a third of survivors. The sample was largely representative of male survivors in Sierra Leone. A limitation of this study is the lack of knowledge about infectiousness.
    Conclusions: In this study we observed that EBOV RNA persistence in semen was a frequent phenomenon, with high population rates over time. This finding will inform forthcoming updated recommendations on risk reduction strategies relating to sexual transmission of EBOV. Our findings support implementation of a semen testing program as part of epidemic preparedness and response. Further, the results will enable planning of the magnitude of testing and targeted counseling needs over time.
    MeSH term(s) Adult ; Aged ; Cohort Studies ; Ebolavirus/genetics ; Ebolavirus/pathogenicity ; Hemorrhagic Fever, Ebola/epidemiology ; Hemorrhagic Fever, Ebola/virology ; Humans ; Male ; Middle Aged ; RNA, Viral/genetics ; Real-Time Polymerase Chain Reaction ; Risk Factors ; Semen/virology ; Survivors/statistics & numerical data
    Chemical Substances RNA, Viral
    Language English
    Publishing date 2021-02-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2185925-5
    ISSN 1549-1676 ; 1549-1277
    ISSN (online) 1549-1676
    ISSN 1549-1277
    DOI 10.1371/journal.pmed.1003273
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.

    Marrinan, Sarah L / Otiker, Tal / Vasist, Lakshmi S / Gibson, Rachel A / Sarai, Bhopinder K / Barton, Matthew E / Richards, Duncan B / Hellström, Per M / Nyholm, Dag / Dukes, George E / Burn, David J

    Movement disorders : official journal of the Movement Disorder Society

    2017  Volume 33, Issue 2, Page(s) 329–332

    Abstract: Background: Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.: Methods: Phase II, double- ... ...

    Abstract Background: Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.
    Methods: Phase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50 mg once-daily (n = 38) or placebo (n = 20) for 7 to 9 days.
    Results: l-dopa exposure was similar with coadministration of camicinal compared to placebo. Median time to maximum l-dopa concentration was reduced, indicating more rapid absorption of l-dopa. Camicinal resulted in significant reduction in OFF time (-2.31 hours; 95% confidence interval: -3.71, -0.90), significant increase in ON time (+1.88 hours; 95% confidence interval: 0.28, 3.48) per day, and significant decrease in mean total MDS-UPDRS score (-12.5; 95% confidence interval: -19.67, -5.29). Camicinal treatment was generally well tolerated.
    Conclusions: PD symptom improvement with camicinal occurred in parallel with more rapid absorption of l-dopa. This study provides evidence of an improvement of the motor response to l-dopa in people with PD treated with camicinal 50 mg once-daily compared with placebo, which will require further evaluation. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Antiparkinson Agents/pharmacokinetics ; Antiparkinson Agents/therapeutic use ; Area Under Curve ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Levodopa/pharmacokinetics ; Levodopa/therapeutic use ; Male ; Middle Aged ; Parkinson Disease/drug therapy ; Piperazines/pharmacokinetics ; Piperazines/therapeutic use ; Piperidines/pharmacokinetics ; Piperidines/therapeutic use ; Statistics, Nonparametric ; Treatment Outcome
    Chemical Substances Antiparkinson Agents ; N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine ; Piperazines ; Piperidines ; Levodopa (46627O600J)
    Language English
    Publishing date 2017-12-26
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 607633-6
    ISSN 1531-8257 ; 0885-3185
    ISSN (online) 1531-8257
    ISSN 0885-3185
    DOI 10.1002/mds.27259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: CD8αα Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection.

    Walker, L J / Marrinan, E / Muenchhoff, M / Ferguson, J / Kloverpris, H / Cheroutre, H / Barnes, E / Goulder, P / Klenerman, Paul

    Frontiers in immunology

    2013  Volume 4, Page(s) 223

    Abstract: The T cell co-receptor CD8αβ enhances T cell sensitivity to antigen, however studies indicate CD8αα has the converse effect and acts as a co-repressor. Using a combination of Thymic Leukemia (TL) antigen tetramer, which directly binds CD8αα, anti-CD161, ... ...

    Abstract The T cell co-receptor CD8αβ enhances T cell sensitivity to antigen, however studies indicate CD8αα has the converse effect and acts as a co-repressor. Using a combination of Thymic Leukemia (TL) antigen tetramer, which directly binds CD8αα, anti-CD161, and anti-Vα7.2 antibodies we have been able for the first time to clearly define CD8αα expression on human CD8 T cells subsets. In healthy controls CD8αα is most highly expressed by CD161 "bright" (CD161++) mucosal associated invariant T (MAIT) cells, with CD8αα expression highly restricted to the TCR Vα7.2+ cells of this subset. We also identified CD8αα-expressing populations within the CD161 "mid" (CD161+) and "negative" (CD161-) non-MAIT CD8 T cell subsets and show TL-tetramer binding to correlate with expression of CD8β at low levels in the context of maintained CD8α expression (CD8α+CD8β(low)). In addition, we found CD161-CD8α+CD8β(low) populations to be significantly expanded in the peripheral blood of HIV-1 and hepatitis B (mean of 47 and 40% of CD161- T cells respectively) infected individuals. Such CD8αα expressing T cells are an effector-memory population (CD45RA-, CCR7-, CD62L-) that express markers of activation and maturation (HLA-DR+, CD28-, CD27-, CD57+) and are functionally distinct, expressing greater levels of TNF-α and IFN-γ on stimulation and perforin at rest than their CD8α+CD8β(high) counterparts. Antigen-specific T cells in HLA-B(∗)4201+HIV-1 infected patients are found within both the CD161-CD8α+CD8β(high) and CD161-CD8α+CD8β(low) populations. Overall we have clearly defined CD8αα expressing human T cell subsets using the TL-tetramer, and have demonstrated CD161-CD8α+CD8β(low) populations, highly expanded in disease settings, to co-express CD8αβ and CD8αα. Co-expression of CD8αα on CD8αβ T cells may impact on their overall function in vivo and contribute to the distinctive phenotype of highly differentiated populations in HBV and HIV-1 infection.
    Language English
    Publishing date 2013-08-06
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2013.00223
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone

    A E Thorson / G F Deen / K T Bernstein / W J Liu / F Yamba / N Habib / F R Sesay / P Gaillard / T A Massaquoi / S L R McDonald / Y Zhang / K N Durski / S Singaravelu / E Ervin / H Liu / A Coursier / J E Marrinan / A Ariyarajah / M Carino /
    P Formenty / U Ströher / M Lamunu / G Wu / F Sahr / W Xu / B Knust / N Broutet / Sierra Leone Ebola Virus Persistence Study Group

    PLoS Medicine, Vol 18, Iss 2, p e

    A cohort study of frequency, duration, and risk factors.

    2021  Volume 1003273

    Abstract: Background Sexual transmission chains of Ebola virus (EBOV) have been verified and linked to EBOV RNA persistence in semen, post-recovery. The rate of semen persistence over time, including the average duration of persistence among Ebola virus disease ( ... ...

    Abstract Background Sexual transmission chains of Ebola virus (EBOV) have been verified and linked to EBOV RNA persistence in semen, post-recovery. The rate of semen persistence over time, including the average duration of persistence among Ebola virus disease (EVD) survivors, is not well known. This cohort study aimed to analyze population estimates of EBOV RNA persistence rates in semen over time, and associated risk factors in a population of survivors from Sierra Leone. Methods and findings In this cohort study from May 2015 to April 2017 in Sierra Leone, recruitment was conducted in 2 phases; the first enrolled 100 male participants from the Western Area District in the capital of Freetown, and the second enrolled 120 men from the Western Area District and from Lungi, Port Loko District. Mean age of participants was 31 years. The men provided semen for testing, analyzed by quantitative reverse transcription PCR (qRT-PCR) for the presence of EBOV RNA. Follow-up occurred every 2 weeks until the endpoint, defined as 2 consecutive negative qRT-PCR results of semen specimen testing for EBOV RNA. Participants were matched with the Sierra Leone EVD case database to retrieve cycle threshold (Ct) values from the qRT-PCR analysis done in blood during acute disease. A purposive sampling strategy was used, and the included sample composition was compared to the national EVD survivor database to understand deviations from the general male survivor population. At 180 days (6 months) after Ebola treatment unit (ETU) discharge, the EBOV RNA semen positive rate was 75.4% (95% CI 66.9%-82.0%). The median persistence duration was 204 days, with 50% of men having cleared their semen of EBOV RNA after this time. At 270 days, persistence was 26.8% (95% CI 20.0%-34.2%), and at 360 days, 6.0% (95% CI 3.1%-10.2%). Longer persistence was significantly associated with severe acute disease, with probability of persistence in this population at 1 year at 10.1% (95% CI 4.6%-19.8%) compared to the probability approaching 0% for those with mild ...
    Keywords Medicine ; R
    Subject code 630
    Language English
    Publishing date 2021-02-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article: Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study.

    Liu, William J / Sesay, Foday R / Coursier, Antoine / Knust, Barbara / Marrinan, Jaclyn E / Whitmer, Shannon / McDonald, Suzanna L R / Gaillard, Philippe / Liu, Yang / Su, Qiudong / Zhang, Yong / Crozier, Ian / Ariyarajah, Archchun / Carino, Marylin / Massaquoi, Thomas / Broutet, Nathalie / Xu, Wenbo / Wu, Guizhen / Ströher, Ute /
    Gao, George F / Formenty, Pierre / Sahr, Foday / Deen, Gibrilla F

    Open forum infectious diseases

    2019  Volume 6, Issue 3, Page(s) ofz068

    Abstract: The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid before 36 days after symptom onset, with nearly an identical genome ... ...

    Abstract The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid before 36 days after symptom onset, with nearly an identical genome sequence as in acute phase blood. Ebola-specific T cells retained activation at 56 days after disease onset.
    Language English
    Publishing date 2019-02-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofz068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Development of risk reduction behavioral counseling for Ebola virus disease survivors enrolled in the Sierra Leone Ebola Virus Persistence Study, 2015-2016.

    Abad, Neetu / Malik, Tasneem / Ariyarajah, Archchun / Ongpin, Patricia / Hogben, Matthew / McDonald, Suzanna L R / Marrinan, Jaclyn / Massaquoi, Thomas / Thorson, Anna / Ervin, Elizabeth / Bernstein, Kyle / Ross, Christine / Liu, William J / Kroeger, Karen / Durski, Kara N / Broutet, Nathalie / Knust, Barbara / Deen, Gibrilla F

    PLoS neglected tropical diseases

    2017  Volume 11, Issue 9, Page(s) e0005827

    Abstract: Background: During the 2014-2016 West Africa Ebola Virus Disease (EVD) epidemic, the public health community had concerns that sexual transmission of the Ebola virus (EBOV) from EVD survivors was a risk, due to EBOV persistence in body fluids of EVD ... ...

    Abstract Background: During the 2014-2016 West Africa Ebola Virus Disease (EVD) epidemic, the public health community had concerns that sexual transmission of the Ebola virus (EBOV) from EVD survivors was a risk, due to EBOV persistence in body fluids of EVD survivors, particularly semen. The Sierra Leone Ebola Virus Persistence Study was initiated to investigate this risk by assessing EBOV persistence in numerous body fluids of EVD survivors and providing risk reduction counseling based on test results for semen, vaginal fluid, menstrual blood, urine, rectal fluid, sweat, tears, saliva, and breast milk. This publication describes implementation of the counseling protocol and the key lessons learned.
    Methodology/principal findings: The Ebola Virus Persistence Risk Reduction Behavioral Counseling Protocol was developed from a framework used to prevent transmission of HIV and other sexually transmitted infections. The framework helped to identify barriers to risk reduction and facilitated the development of a personalized risk-reduction plan, particularly around condom use and abstinence. Pre-test and post-test counseling sessions included risk reduction guidance, and post-test counseling was based on the participants' individual test results. The behavioral counseling protocol enabled study staff to translate the study's body fluid test results into individualized information for study participants.
    Conclusions/significance: The Ebola Virus Persistence Risk Reduction Behavioral Counseling Protocol provided guidance to mitigate the risk of EBOV transmission from EVD survivors. It has since been shared with and adapted by other EVD survivor body fluid testing programs and studies in Ebola-affected countries.
    MeSH term(s) Behavior Therapy ; Counseling ; Disease Transmission, Infectious/prevention & control ; Female ; Hemorrhagic Fever, Ebola/epidemiology ; Hemorrhagic Fever, Ebola/prevention & control ; Humans ; Male ; Risk-Taking ; Sexual Behavior ; Sierra Leone/epidemiology ; Survivors
    Language English
    Publishing date 2017-09-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2429704-5
    ISSN 1935-2735 ; 1935-2735
    ISSN (online) 1935-2735
    ISSN 1935-2735
    DOI 10.1371/journal.pntd.0005827
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top